{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:42:20Z","timestamp":1778078540339,"version":"3.51.4"},"reference-count":42,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T00:00:00Z","timestamp":1707609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Optimal urine-based diagnostic tests (UBDT) minimize unnecessary follow-up cystoscopies in patients with non-muscle-invasive bladder-cancer (NMIBC), while accurately detecting high-grade bladder-cancer without false-negative results. Such UBDTs have not been comprehensively described upon a broad, validated dataset, resulting in cautious guideline recommendations. Uromonitor\u00ae, a urine-based DNA-assay detecting hotspot alterations in TERT, FGFR3, and KRAS, shows promising initial results. However, a systematic review merging all available data is lacking. Studies investigating the diagnostic performance of Uromonitor\u00ae in NMIBC until November 2023 were identified in PubMed, Embase, Web-of-Science, Cochrane, Scopus, and medRxiv databases. Within aggregated analyses, test performance and area under the curve\/AUC were calculated. This project fully implemented the PRISMA statement. Four qualifying studies comprised a total of 1190 urinary tests (bladder-cancer prevalence: 14.9%). Based on comprehensive analyses, sensitivity, specificity, positive-predictive value\/PPV, negative-predictive value\/NPV, and test accuracy of Uromonitor\u00ae were 80.2%, 96.9%, 82.1%, 96.6%, and 94.5%, respectively, with an AUC of 0.886 (95%-CI: 0.851\u20130.921). In a meta-analysis of two studies comparing test performance with urinary cytology, Uromonitor\u00ae significantly outperformed urinary cytology in sensitivity, PPV, and test accuracy, while no significant differences were observed for specificity and NPV. This systematic review supports the use of Uromonitor\u00ae considering its favorable diagnostic performance. In a cohort of 1000 patients with a bladder-cancer prevalence of ~15%, this UBDT would avert 825 unnecessary cystoscopies (true-negatives) while missing 30 bladder-cancer cases (false-negatives). Due to currently limited aggregated data from only four studies with heterogeneous quality, confirmatory studies are needed.<\/jats:p>","DOI":"10.3390\/cancers16040753","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:19:59Z","timestamp":1707718799000},"page":"753","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Urine-Based Biomarker Test Uromonitor\u00ae in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer\u2014A Systematic Review and Meta-Analysis of Diagnostic Test Performance"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3365-1563","authenticated-orcid":false,"given":"Anton P.","family":"Kravchuk","sequence":"first","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-6643","authenticated-orcid":false,"given":"Ingmar","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-0636","authenticated-orcid":false,"given":"Christian","family":"Gilfrich","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany"}]},{"given":"Ralph M.","family":"Wirtz","sequence":"additional","affiliation":[{"name":"STRATIFYER Molecular Pathology GmbH, 50935 Cologne, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9607-6998","authenticated-orcid":false,"given":"Paula","family":"Soares","sequence":"additional","affiliation":[{"name":"IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, 4200-135 Porto, Portugal"},{"name":"Department of Pathology and Oncology, Faculty of Medicine, University of Porto, 4200-139 Porto, Portugal"}]},{"given":"Kay-Patrick","family":"Braun","sequence":"additional","affiliation":[{"name":"Institute of General Practice, Otto-von-Guericke-University Magdeburg, 39120 Magdeburg, Germany"}]},{"given":"Sabine D.","family":"Brookman-May","sequence":"additional","affiliation":[{"name":"Department of Urology, Ludwig-Maximilians-University, 81377 Munich, Germany"},{"name":"Johnson and Johnson Innovative Medicine, Research & Development, Spring House, PA 19477, USA"}]},{"given":"Lisa","family":"Kollitsch","sequence":"additional","affiliation":[{"name":"Department of Urology and Andrology, Klinik Donaustadt, A1220 Vienna, Austria"}]},{"given":"Katharina","family":"Hauner","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital MRI-TUM (M\u00fcnchen rechts der Isar), 81675 Munich, Germany"}]},{"given":"Martin","family":"Burchardt","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany"}]},{"given":"Johannes","family":"Br\u00fcndl","sequence":"additional","affiliation":[{"name":"Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, 93053 Regensburg, Germany"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, 93053 Regensburg, Germany"}]},{"given":"Matthias","family":"May","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, 94315 Straubing, Germany"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.urology.2007.04.023","article-title":"Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice","volume":"70","author":"May","year":"2007","journal-title":"Urology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"484.e17","DOI":"10.1016\/j.urolonc.2023.06.013","article-title":"BTA stat\u00ae, NMP22\u00ae BladderChek\u00ae, UBC\u00ae Rapid Test, and CancerCheck\u00ae UBC\u00ae rapid VISUAL as urinary marker for bladder cancer: Final results of a German multicenter study","volume":"41","author":"Ecke","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ucl.2022.09.009","article-title":"Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer","volume":"50","author":"Lotan","year":"2023","journal-title":"Urol. Clin. N. Am."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Lee, D., Lee, W., Kim, H.P., Kim, M., Ahn, H.K., Bang, D., and Kim, K.H. (2023). Accurate Detection of Urothelial Bladder Cancer Using Targeted Deep Sequencing of Urine DNA. Cancers, 15.","DOI":"10.3390\/cancers15102868"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Papavasiliou, E., Sills, V.A., Calanzani, N., Harrison, H., Snudden, C., di Martino, E., Cowan, A., Behiyat, D., Boscott, R., and Tan, S. (2023). Diagnostic Performance of Biomarkers for Bladder Cancer Detection Suitable for Community and Primary Care Settings: A Systematic Review and Meta-Analysis. Cancers, 15.","DOI":"10.3390\/cancers15030709"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Zhang, J., Xu, R., Lu, Q., Xu, Z., Liu, J., Li, P., Zhang, Y., Zhou, C., Luo, L., and Tang, W. (2023). A Novel Methylation Marker NRN1 plus TERT and FGFR3 Mutation Using Urine Sediment Enables the Detection of Urothelial Bladder Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15030615"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Hu, X., Li, G., and Wu, S. (2022). Advances in Diagnosis and Therapy for Bladder Cancer. Cancers, 14.","DOI":"10.3390\/cancers14133181"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ibrahim, N.K., Eraky, A., Eggers, J., Steiert, T.A., Sebens, S., Junemann, K.P., Hendricks, A., Bang, C., Stanulla, M., and Franke, A. (2022). Detection of Cancer Mutations by Urine Liquid Biopsy as a Potential Tool in the Clinical Management of Bladder Cancer Patients. Cancers, 14.","DOI":"10.3390\/cancers14040969"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Singer, G., Ramakrishnan, V.M., Rogel, U., Schotzau, A., Disteldorf, D., Maletzki, P., Adank, J.P., Hofmann, M., Niemann, T., and Stadlmann, S. (2022). The Role of New Technologies in the Diagnosis and Surveillance of Non-Muscle Invasive Bladder Carcinoma: A Prospective, Double-Blinded, Monocentric Study of the XPERT(c) Bladder Cancer Monitor and Narrow Band Imaging(c) Cystoscopy. Cancers, 14.","DOI":"10.3390\/cancers14030618"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1002\/bco2.234","article-title":"Perception of urinary biomarker tests among patients referred with suspected urological malignancy","volume":"4","author":"Bullock","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhao, J., Li, J., and Zhang, R. (2023). Off the fog to find the optimal choice: Research advances in biomarkers for early diagnosis and recurrence monitoring of bladder cancer. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2023.188926"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"11503","DOI":"10.1002\/cam4.5879","article-title":"Detection of the ADGRG6 hotspot mutations in urine for bladder cancer early screening by ARMS-qPCR","volume":"12","author":"Tan","year":"2023","journal-title":"Cancer Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Jain, M., Tivtikyan, A., Kamalov, D., Avdonin, S., Rakhmatullin, T., Pisarev, E., Zvereva, M., Samokhodskaya, L., and Kamalov, A. (2023). Development of a Sensitive Digital Droplet PCR Screening Assay for the Detection of GPR126 Non-Coding Mutations in Bladder Cancer Urine Liquid Biopsies. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020495"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"710","DOI":"10.52547\/rbmb.11.4.710","article-title":"Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer","volume":"11","author":"Rasti","year":"2023","journal-title":"Rep. Biochem. Mol. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/bju.15677","article-title":"Nomograms including the UBC\u00ae Rapid test to detect primary bladder cancer based on a multicentre dataset","volume":"130","author":"Meisl","year":"2022","journal-title":"BJU Int."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2147\/CEOR.S274951","article-title":"Humanistic and Economic Burden of Non-Muscle Invasive Bladder Cancer: Results of Two Systematic Literature Reviews","volume":"12","author":"Lee","year":"2020","journal-title":"Clin. Outcomes Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Sieverink, C.A., Batista, R.P.M., Prazeres, H.J.M., Vinagre, J., Sampaio, C., Leao, R.R., Maximo, V., Witjes, J.A., and Soares, P. (2020). Clinical Validation of a Urine Test (Uromonitor-V2\u00ae) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics, 10.","DOI":"10.3390\/diagnostics10100745"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.3389\/fgene.2019.01237","article-title":"Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients With Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study","volume":"10","author":"Batista","year":"2019","journal-title":"Front. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Schunemann","year":"2008","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Azawi, N., Vasquez, J.L., Dreyer, T., Guldhammer, C.S., Saber Al-Juboori, R.M., Nielsen, A.M., and Jensen, J.B. (2023). Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial. Cancers, 15.","DOI":"10.3390\/cancers15082341"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ramos, P., Br\u00e1s, J.P., Dias, C., Bessa-Gon\u00e7alves, M., Prazeres, H., Botelho, F., Silva, J., Silva, C., and Pacheco-Figueiredo, L. (2024). Uromonitor\u00ae: Clinical Validation and Performance Assessment of a Urinary Biomarker for Recurrence Surveillance in Non-Muscle Invasive Bladder Cancer Patients. medRxiv.","DOI":"10.1101\/2023.11.02.23297958"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"66.e25","DOI":"10.1016\/j.urolonc.2014.06.008","article-title":"Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer","volume":"33","author":"Yafi","year":"2015","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0022-5347(17)69643-5","article-title":"Cytology of the urine sediment in neoplasms of the urinary tract","volume":"57","author":"Papanicolaou","year":"1947","journal-title":"J. Urol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"15437","DOI":"10.1038\/s41598-023-42088-z","article-title":"Xpert bladder cancer monitor to predict the need for a second TURB (MoniTURB trial)","volume":"13","author":"Breyer","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S0302-2838(02)00006-4","article-title":"Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis","volume":"41","author":"Raitanen","year":"2002","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1464-410X.2006.06036.x","article-title":"Institutional variability in the accuracy of urinary cytology for predicting recurrence of transitional cell carcinoma of the bladder","volume":"97","author":"Karakiewicz","year":"2006","journal-title":"BJU Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2022.40.6_suppl.469","article-title":"FGFR testing and urine-based risk straticfication from matched tissue and urine samples within the prospective real-world clinicopathological register trial: BRIDGister","volume":"40","author":"Wirtz","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e16532","DOI":"10.1200\/JCO.2021.39.15_suppl.e16532","article-title":"FGFR testing from matched tissue and urine samples within the prospective real world clinico-pathological register trial BRIDGister","volume":"39","author":"Wirtz","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Vilaseca, A., Guerrero, F., Zainfeld, D., Shore, N.D., Rodr\u00edguez Faba, \u00d3., Meijer, R.P., Witjes, A.A., Mcree, A.J., Kalota, A., and Stone, N.L. (2023). Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non\u2013muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: Phase 1 first-in-human study. J. Clin. Oncol., 41.","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS583"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832835","DOI":"10.3389\/fonc.2022.832835","article-title":"Xpert Bladder Cancer Monitor May Avoid Cystoscopies in Patients Under \u201cActive Surveillance\u201d for Recurrent Bladder Cancer (BIAS Project): Longitudinal Cohort Study","volume":"12","author":"Fasulo","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00345-022-04252-4","article-title":"Bladder EpiCheck urine test in the follow-up of NMIBC: A cost analysis","volume":"41","author":"Hekman","year":"2023","journal-title":"World J. Urol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"326 e321","DOI":"10.1016\/j.urolonc.2023.01.009","article-title":"Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer","volume":"41","author":"Li","year":"2023","journal-title":"Urol. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.euf.2022.02.006","article-title":"Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker","volume":"8","author":"Roupret","year":"2022","journal-title":"Eur. Urol. Focus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S868","DOI":"10.1016\/S0302-2838(23)00655-3","article-title":"The value of urinary based rapid tests during follow-up in bladder cancer: BTA stat\u00ae, Alere NMP22\u00ae BladderChek\u00ae, UBC\u00ae rapid test, CancerCheck\u00ae UBC\u00ae rapid VISUAL, and uromonitor\u00ae in comparison to cytology","volume":"83","author":"Ecke","year":"2023","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.21873\/anticanres.16031","article-title":"Luminophore Chemistry for Detection of Urinary Bladder Cancer\u2014Comparison to Cytology and Urinary Rapid Tests (BTA stat\u00ae, NMP22\u00ae BladderChek\u00ae and UBC\u00ae Rapid Test)","volume":"42","author":"Ecke","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1038\/s41416-022-01992-3","article-title":"Multicentric validation of diagnostic tests based on BC-116 and BC-106 urine peptide biomarkers for bladder cancer in two prospective cohorts of patients","volume":"127","author":"Mengual","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"296.e1","DOI":"10.1016\/j.urolonc.2022.12.012","article-title":"Performance of CellDetect for detection of bladder cancer: Comparison with urine cytology and UroVysion","volume":"41","author":"Shefer","year":"2023","journal-title":"Urol. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/753\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:58:44Z","timestamp":1760104724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,11]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040753"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040753","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,11]]}}}